Developer docs
API playgroundTry for free, no card

Search company profiles

VIDA

Full company profile

uuid0000ejq

Namestring
VIDA
Legal namestring
VIDA Diagnostics, Inc.
Websiteurl
vidalung.ai
Company typeenum
Private
Founded yearint
2009
Descriptiontext

VIDA Diagnostics is a clinical imaging intelligence company founded in 2009 and headquartered in Coralville, Iowa, that builds AI-powered quantitative imaging biomarker solutions for respiratory, cardiovascular, and oncology clinical trials. Its core technology is the VIDA Intelligence Platform, a cloud-based system that ingests chest CT and, increasingly, MRI scans and applies proprietary deep-learning algorithms to extract up to 15,000 individual metrics per scan spanning 50+ biomarkers covering airway, parenchymal, vascular, and functional lung characteristics. The platform supports AI-powered digital biomarker analysis, expert reading services (eligibility reads, safety reads, adjudication), site onboarding and scanner certification, and sponsor trial orchestration, all backed by a Digital Biobank containing over 1 billion biological metrics, 500+ terabytes of multi-omic data, and records from more than 500,000 patients.

VIDA's product portfolio includes the VIDA Intelligence Platform (core cloud infrastructure), VIDA Discovery (clinical trial imaging services, formerly LungPrint Discovery), VIDA Insights (FDA-cleared point-of-care clinical software), the DTA Fibrosis Score for ILD, and a Cloud-Based Case Viewer. The company has built a dual distribution model combining direct enterprise sales to biopharma sponsors with channel partnerships through Nuance AI Marketplace (reaching 70% of US radiologists across 6,000+ facilities), TeraRecon EnvoyAI, Blackford, and IBM Watson Health. Revenue is generated primarily through enterprise service contracts for clinical trial imaging, recurring software licensing for VIDA Insights, and platform access fees, with regulatory clearances across the United States (FDA 510(k)), European Union (CE Mark), Canada, Australia (TGA), and Japan (PMDA) enabling global commercial reach.

VIDA has cumulatively raised approximately $33 million in venture funding, including a $13 million Series C in 2020 and a ~$10.8 million growth round in September 2023, with strategic investments from healthcare systems such as UnityPoint Health Ventures, OSF Ventures, and UW Health. The company has supported 60+ clinical trials across 30+ countries, operates a network of 1,500+ trial sites with 5,000+ users, and was recognized on the 2023 Inc. 5000 list for revenue growth and by Frost & Sullivan as 2020 Global Company of the Year in the radiology AI market for lung care. Recent strategic priorities include expansion into cardiovascular and oncology trial imaging, entry into functional MRI modalities through the Polarean partnership, and ecosystem-level integration of third-party algorithms from Riverain, Thirona, and other imaging AI specialists.

Short descriptiontext

VIDA Diagnostics provides AI-powered quantitative imaging biomarker analysis and clinical trial imaging services to biopharma sponsors. Its cloud-based VIDA Intelligence Platform analyzes CT and MRI scans for respiratory, cardiovascular, and oncology trials, supported by a digital biobank of 500,000+ patients.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersCoralville, United States
HQ citystring
Coralville
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical trial imaging, AI-powered biomarkers, pulmonary imaging software, medical imaging analytics, quantitative CT biomarkers
Industry3 codes
PRIMARYHLAGAJAM
Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGACAG
Clinical Trial Monitoring Support (On-site/Remote)
SECONDARYHLAGACAB
Site Identification & Feasibility
NAICS code1 code
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Clinical Imaging Intelligence
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Clinical Trial Imaging Services
TypeSubscription Recurring
Description

VIDA provides platform-enabled clinical trial imaging services to biopharma sponsors, including site management, imaging data collection, AI-powered biomarker analysis, and expert reading services. Revenue derived from service contracts with pharmaceutical companies conducting imaging-based clinical trials.

vidalung.ai
2Software Licensing (VIDA Insights/LungPrint)
TypeSubscription Recurring
Description

Licensing of FDA-cleared, CE-marked software solutions for clinical use. Software available in US, EU, Canada, Australia, and Japan through distribution partnerships and direct sales.

vidalung.ai
3Platform Access and Integration
TypeSubscription Recurring
Description

Cloud-based platform access provided to trial sites and sponsors, with integration into partner platforms (Nuance, TeraRecon, Blackford) expanding market reach and revenue opportunities.

vidalung.ai
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 4 records shown
1LungPrint
Description

AI-powered imaging suite for pulmonary care, including LungPrint Discovery for automated radiological metrics and unique airway visualizations. LungPrint helps detect COPD and interstitial lung disease.

vidalung.ai
+3 more records
Core offering1 text field

VIDA Diagnostics provides AI-powered clinical trial imaging services and software to biopharma sponsors, enabling the collection, management, and analysis of quantitative imaging biomarkers throughout the drug development process. Its VIDA Intelligence Platform supports site management, trial orchestration, expert reading services, and AI-driven biomarker analysis across 1,500+ global sites, complemented by FDA-cleared clinical software (VIDA Insights/LungPrint) used by radiologists and pulmonologists at the point of care for early disease detection.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 700% growth in utilization of imaging biomarkers in clinical trials
+4 more records
Product overview1 text field

VIDA is a clinical imaging intelligence company offering a platform-plus-modules architecture. The VIDA Intelligence Platform serves as the core cloud infrastructure enabling clinical trial imaging management and digital biobank capabilities. This platform is powered by two main product lines: VIDA Discovery (clinical trial services) and VIDA Insights (clinical care, formerly LungPrint). Supporting modules include the VIDA Intelligence Portal for trial site management, Cloud-Based Case Viewer for workflow efficiency, Digital Biobank for patient data repositories, DTA Fibrosis Score for ILD quantification, and comprehensive ILD imaging solutions. The portfolio also integrates best-of-breed partner algorithms including Thirona for thoracic imaging, Riverain for CT analysis, and Polarean for Xenon MRI functional assessment.

Product and service3 records
1VIDA Intelligence Platform
CategoryCloud Platform
Description

AI-powered cloud platform enabling biopharma sponsors to collect and leverage high-quality imaging data throughout drug development and clinical trial processes. Powers digital biobank, site operations, trial orchestration, and biomarker analysis across 1,500+ global sites.

2VIDA Insights (formerly LungPrint)
CategoryClinical Software
Description

FDA-cleared, CE-marked, Health Canada, TGA, and PMDA-certified AI-powered clinical solution for lung care teams to detect disease early, diagnose with confidence, and make personalized treatment decisions at the point of care.

3VIDA Discovery (formerly LungPrint Discovery)
Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-01-21
Description

VIDA partnered with Polarean to integrate Xenon MRI biomarker analysis into its clinical trial platform. VIDA provides centralized imaging operations and advanced biomarker analysis for Polarean's multi-center U.S. study in PH-ILD, enabling non-invasive, radiation-free imaging of the pulmonary capillary bed for cardiopulmonary drug development.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-12-01
Description

Strategic partnership to integrate Riverain's ClearRead CT AI imaging analysis suite into VIDA's clinical trial platform. The collaboration aims to enhance biomarker data quality and operational efficiency for diseases like COPD, cardiovascular disease, and lung cancer, which collectively cause 40% of global deaths.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-09-27
Description

VIDA partnered with Thirona to expand respiratory clinical trial imaging capabilities. Thirona provides advanced AI-powered analysis of thoracic imaging built on robust segmentation and precise quantification of bronchial, parenchymal, and vascular lung structures, available through VIDA's trial imaging solutions.

4OSIC (Open Source Imaging Consortium)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

VIDA's cloud platform powers OSIC Cloud, the world's largest and most diverse global repository for interstitial lung diseases. VIDA serves as both member and platform partner for OSIC, supporting its bold mission to advance ILD research and treatment.

blog.vidalung.ai
5AWS (Amazon Web Services)
Strategic tierCoreTypeTechnology or Integration
Description

VIDA leverages AWS cloud technologies for the VIDA Intelligence Platform, enabling scalable, secure cloud infrastructure for clinical trial imaging data management and analysis.

vidalung.ai
Strategic tierCoreTypeStrategic or Co-development Partner
Description

VIDA licensed the DTA (Data-Driven Texture Analysis) Fibrosis Score from National Jewish Health. The deep learning solution automatically quantifies lung fibrosis on HRCT scans and has been applied to tens of thousands of scans from diverse clinical trials, registries, and research cohorts.

Strategic tierMajorTypeChannel Partner/ Reseller/ Distributor
Description

Distribution partner integrating LungPrint suite into radiology workflow for broader market access.

Strategic tierMajorTypeChannel Partner/ Reseller/ Distributor
Description

Distribution partner for LungPrint suite integration into Watson Health ecosystem for enterprise healthcare customers.

Strategic tierMajorTypeChannel Partner/ Reseller/ Distributor
Description

VIDA joined Nuance AI Marketplace making LungPrint Discovery available to 70% of radiologists across 6,000+ healthcare facilities. Integrated with PowerScribe One radiology reporting platform.

10TeraRecon
Strategic tierMajorTypeChannel Partner/ Reseller/ Distributor
Description

Distribution agreement with TeraRecon for LungPrint availability through AI Interoperability platform EnvoyAI, creating integrated physician experience.

blog.vidalung.ai
Strategic tierStrategicTypeStrategic or Co-development Partner
Description

VIDA and RAYUS Radiology partnered to empower imaging sites for decentralized clinical trials, enabling efficient trial participation.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Median Technologies provides AI-driven imaging biomarkers and imaging trial management services to biopharma sponsors, with a particular focus on oncology. It is a directly comparable clinical trial imaging AI peer, operating in the same iCRO/imaging core lab category with similar SaaS-plus-services revenue model.

TypeDirect peer
Description

Clario is a leading clinical trial endpoint and imaging core lab provider, offering centralized imaging services and software for clinical trials across multiple therapeutic areas. It directly competes with VIDA in respiratory/cardiac imaging core lab services and has substantially larger scale and sponsor footprint.

TypeBroad incumbent
Description

IQVIA is the world's largest CRO with embedded clinical trial imaging, real-world evidence, and data services. While broader and less specialized than VIDA, it competes for the same biopharma imaging endpoint budget and increasingly offers AI-driven imaging analytics as part of its portfolio.

TypeDirect peer
Description

Medidata provides the Medidata Rave clinical trial platform including imaging management and eCOA capabilities used by sponsors globally. It is a peer in clinical trial informatics technology — the same category as VIDA's Intelligence Platform — and competes for sponsor technology budget.

TypeBroad incumbent
Description

ICON plc is a global CRO with significant imaging and biomarker capabilities following its PRA Health Sciences and other acquisitions. It competes with VIDA for biopharma clinical trial imaging contracts but at a much broader scale across all therapeutic areas.

TypeEmerging player
Description

Aidoc is a leading clinical AI imaging platform deployed across hospital systems, with FDA-cleared algorithms spanning multiple body parts. It is an emerging competitor in radiology AI infrastructure and could expand into respiratory imaging where VIDA is specialized.

TypeBroad incumbent
Description

Veeva provides cloud-based life sciences industry software, including Veeva Vault CTMS and eTMF for clinical trials. It is a broader incumbent in clinical trial technology that competes with VIDA's Intelligence Platform for sponsor platform budget.

TypeEmerging player
Description

Arterys, now part of Tempus, offers cloud-based AI medical imaging platforms with FDA-cleared algorithms for cardiac and lung MRI/CT. It is an emerging peer in clinical imaging AI infrastructure with comparable cloud-native architecture.

TypeDirect peer
Description

Riverain Technologies provides AI-enabled chest CT analysis tools (ClearRead) for nodules, CAC, and lung tissue quantification — overlapping directly with VIDA's LungPrint. Notably, Riverain is now also a VIDA integration partner, reflecting both competitive and collaborative dynamics.

10Biomedical Systems (ERT/Clario)
TypeDirect peer
Description

Biomedical Systems, now part of Clario, is a longstanding clinical trial imaging core lab with cardiac and respiratory imaging experience. It directly competes with VIDA for respiratory and cardiac imaging endpoint work in biopharma-sponsored trials.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat7 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration6 records

Each record includes

Title, Type, Description, Source

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance9 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors13 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

VIDA

Clinical Imaging Intelligencevidalung.ai

VIDA Diagnostics provides AI-powered quantitative imaging biomarker analysis and clinical trial imaging services to biopharma sponsors. Its cloud-based VIDA Intelligence Platform analyzes CT and MRI scans for respiratory, cardiovascular, and oncology trials, supported by a digital biobank of 500,000+ patients.

What VIDA does

VIDA Diagnostics is a clinical imaging intelligence company founded in 2009 and headquartered in Coralville, Iowa, that builds AI-powered quantitative imaging biomarker solutions for respiratory, cardiovascular, and oncology clinical trials. Its core technology is the VIDA Intelligence Platform, a cloud-based system that ingests chest CT and, increasingly, MRI scans and applies proprietary deep-learning algorithms to extract up to 15,000 individual metrics per scan spanning 50+ biomarkers covering airway, parenchymal, vascular, and functional lung characteristics. The platform supports AI-powered digital biomarker analysis, expert reading services (eligibility reads, safety reads, adjudication), site onboarding and scanner certification, and sponsor trial orchestration, all backed by a Digital Biobank containing over 1 billion biological metrics, 500+ terabytes of multi-omic data, and records from more than 500,000 patients.

VIDA's product portfolio includes the VIDA Intelligence Platform (core cloud infrastructure), VIDA Discovery (clinical trial imaging services, formerly LungPrint Discovery), VIDA Insights (FDA-cleared point-of-care clinical software), the DTA Fibrosis Score for ILD, and a Cloud-Based Case Viewer. The company has built a dual distribution model combining direct enterprise sales to biopharma sponsors with channel partnerships through Nuance AI Marketplace (reaching 70% of US radiologists across 6,000+ facilities), TeraRecon EnvoyAI, Blackford, and IBM Watson Health. Revenue is generated primarily through enterprise service contracts for clinical trial imaging, recurring software licensing for VIDA Insights, and platform access fees, with regulatory clearances across the United States (FDA 510(k)), European Union (CE Mark), Canada, Australia (TGA), and Japan (PMDA) enabling global commercial reach.

VIDA has cumulatively raised approximately $33 million in venture funding, including a $13 million Series C in 2020 and a ~$10.8 million growth round in September 2023, with strategic investments from healthcare systems such as UnityPoint Health Ventures, OSF Ventures, and UW Health. The company has supported 60+ clinical trials across 30+ countries, operates a network of 1,500+ trial sites with 5,000+ users, and was recognized on the 2023 Inc. 5000 list for revenue growth and by Frost & Sullivan as 2020 Global Company of the Year in the radiology AI market for lung care. Recent strategic priorities include expansion into cardiovascular and oncology trial imaging, entry into functional MRI modalities through the Polarean partnership, and ecosystem-level integration of third-party algorithms from Riverain, Thirona, and other imaging AI specialists.

VIDA firmographics

Firmographics
Name
VIDA
Legal name
VIDA Diagnostics, Inc.
Website
https://vidalung.ai
Company type
Private
Founded year
2009
Operating status
Operating
Headcount range
51–100 employees
Short description
VIDA Diagnostics provides AI-powered quantitative imaging biomarker analysis and clinical trial imaging services to biopharma sponsors. Its cloud-based VIDA Intelligence Platform analyzes CT and MRI scans for respiratory, cardiovascular, and oncology trials, supported by a digital biobank of 500,000+ patients.
Ownership category
akta.pro rank

VIDA industry classification

Industry
Product category
Clinical Imaging Intelligence
NAICS
Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAJAM
Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGACAG
Clinical Trial Monitoring Support (On-site/Remote)
SECONDARYHLAGACAB
Site Identification & Feasibility

Keywords

  • Clinical trial imaging
  • AI-powered biomarkers
  • Pulmonary imaging software
  • Medical imaging analytics
  • Quantitative CT biomarkers

Where VIDA is headquartered

Location

Headquarters

HQ city
Coralville
HQ country
United States
HQ region
North America

Offices1 record

Markets served

VIDA business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Clinical Trial Imaging Services: VIDA provides platform-enabled clinical trial imaging services to biopharma sponsors, including site management, imaging data collection, AI-powered biomarker analysis, and expert reading services. Revenue derived from service contracts with pharmaceutical companies conducting imaging-based clinical trials.
  2. Software Licensing (VIDA Insights/LungPrint): Licensing of FDA-cleared, CE-marked software solutions for clinical use. Software available in US, EU, Canada, Australia, and Japan through distribution partnerships and direct sales.
  3. Platform Access and Integration: Cloud-based platform access provided to trial sites and sponsors, with integration into partner platforms (Nuance, TeraRecon, Blackford) expanding market reach and revenue opportunities.

Go-to-market motion2 records

Distribution channels6 records

Marketing channels7 records

VIDA product offering

Product offering

Core offering

VIDA Diagnostics provides AI-powered clinical trial imaging services and software to biopharma sponsors, enabling the collection, management, and analysis of quantitative imaging biomarkers throughout the drug development process. Its VIDA Intelligence Platform supports site management, trial orchestration, expert reading services, and AI-driven biomarker analysis across 1,500+ global sites, complemented by FDA-cleared clinical software (VIDA Insights/LungPrint) used by radiologists and pulmonologists at the point of care for early disease detection.

Product overview

VIDA is a clinical imaging intelligence company offering a platform-plus-modules architecture. The VIDA Intelligence Platform serves as the core cloud infrastructure enabling clinical trial imaging management and digital biobank capabilities. This platform is powered by two main product lines: VIDA Discovery (clinical trial services) and VIDA Insights (clinical care, formerly LungPrint). Supporting modules include the VIDA Intelligence Portal for trial site management, Cloud-Based Case Viewer for workflow efficiency, Digital Biobank for patient data repositories, DTA Fibrosis Score for ILD quantification, and comprehensive ILD imaging solutions. The portfolio also integrates best-of-breed partner algorithms including Thirona for thoracic imaging, Riverain for CT analysis, and Polarean for Xenon MRI functional assessment.

Differentiator

Problem solved

Functional benefit

Brands

  • LungPrint: AI-powered imaging suite for pulmonary care, including LungPrint Discovery for automated radiological metrics and unique airway visualizations. LungPrint helps detect COPD and interstitial lung disease.
  • VIDA Insights
  • VIDA Intelligence Platform
  • Digital Biobank

Products and services

  • VIDA Intelligence Platform AI-powered cloud platform enabling biopharma sponsors to collect and leverage high-quality imaging data throughout drug development and clinical trial processes. Powers digital biobank, site operations, trial orchestration, and biomarker analysis across 1,500+ global sites.
  • VIDA Insights (formerly LungPrint) FDA-cleared, CE-marked, Health Canada, TGA, and PMDA-certified AI-powered clinical solution for lung care teams to detect disease early, diagnose with confidence, and make personalized treatment decisions at the point of care.
  • VIDA Discovery (formerly LungPrint Discovery)

Quantifiable outcome

  • 700% growth in utilization of imaging biomarkers in clinical trials
  • +4 more outcomes

Companies that use VIDA

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles3 records

VIDA technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration6 records

AI capability6 records

Feature8 records

VIDA partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered core, major and strategic.

  • PolareancoreTechnology or Integration · 21 January 2026VIDA partnered with Polarean to integrate Xenon MRI biomarker analysis into its clinical trial platform. VIDA provides centralized imaging operations and advanced biomarker analysis for Polarean's multi-center U.S. study in PH-ILD, enabling non-invasive, radiation-free imaging of the pulmonary capillary bed for cardiopulmonary drug development.
  • Riverain TechnologiescoreTechnology or Integration · 1 December 2025Strategic partnership to integrate Riverain's ClearRead CT AI imaging analysis suite into VIDA's clinical trial platform. The collaboration aims to enhance biomarker data quality and operational efficiency for diseases like COPD, cardiovascular disease, and lung cancer, which collectively cause 40% of global deaths.
  • ThironacoreTechnology or Integration · 27 September 2025VIDA partnered with Thirona to expand respiratory clinical trial imaging capabilities. Thirona provides advanced AI-powered analysis of thoracic imaging built on robust segmentation and precise quantification of bronchial, parenchymal, and vascular lung structures, available through VIDA's trial imaging solutions.
  • OSIC (Open Source Imaging Consortium)coreStrategic or Co-development PartnerVIDA's cloud platform powers OSIC Cloud, the world's largest and most diverse global repository for interstitial lung diseases. VIDA serves as both member and platform partner for OSIC, supporting its bold mission to advance ILD research and treatment.
  • AWS (Amazon Web Services)coreTechnology or IntegrationVIDA leverages AWS cloud technologies for the VIDA Intelligence Platform, enabling scalable, secure cloud infrastructure for clinical trial imaging data management and analysis.
  • National Jewish HealthcoreStrategic or Co-development PartnerVIDA licensed the DTA (Data-Driven Texture Analysis) Fibrosis Score from National Jewish Health. The deep learning solution automatically quantifies lung fibrosis on HRCT scans and has been applied to tens of thousands of scans from diverse clinical trials, registries, and research cohorts.
  • BlackfordmajorChannel Partner/ Reseller/ DistributorDistribution partner integrating LungPrint suite into radiology workflow for broader market access.
  • IBM Watson HealthmajorChannel Partner/ Reseller/ DistributorDistribution partner for LungPrint suite integration into Watson Health ecosystem for enterprise healthcare customers.
  • Nuance CommunicationsmajorChannel Partner/ Reseller/ DistributorVIDA joined Nuance AI Marketplace making LungPrint Discovery available to 70% of radiologists across 6,000+ healthcare facilities. Integrated with PowerScribe One radiology reporting platform.
  • TeraReconmajorChannel Partner/ Reseller/ DistributorDistribution agreement with TeraRecon for LungPrint availability through AI Interoperability platform EnvoyAI, creating integrated physician experience.
  • RAYUS RadiologystrategicStrategic or Co-development PartnerVIDA and RAYUS Radiology partnered to empower imaging sites for decentralized clinical trials, enabling efficient trial participation.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

VIDA competitors and assessment

Company assessment

Direct peers

  • Median Technologies: Median Technologies provides AI-driven imaging biomarkers and imaging trial management services to biopharma sponsors, with a particular focus on oncology. It is a directly comparable clinical trial imaging AI peer, operating in the same iCRO/imaging core lab category with similar SaaS-plus-services revenue model.
  • Clario (formerly Bioclinica): Clario is a leading clinical trial endpoint and imaging core lab provider, offering centralized imaging services and software for clinical trials across multiple therapeutic areas. It directly competes with VIDA in respiratory/cardiac imaging core lab services and has substantially larger scale and sponsor footprint.
  • Medidata (Dassault Systèmes): Medidata provides the Medidata Rave clinical trial platform including imaging management and eCOA capabilities used by sponsors globally. It is a peer in clinical trial informatics technology — the same category as VIDA's Intelligence Platform — and competes for sponsor technology budget.
  • Riverain Technologies: Riverain Technologies provides AI-enabled chest CT analysis tools (ClearRead) for nodules, CAC, and lung tissue quantification — overlapping directly with VIDA's LungPrint. Notably, Riverain is now also a VIDA integration partner, reflecting both competitive and collaborative dynamics.
  • Biomedical Systems (ERT/Clario): Biomedical Systems, now part of Clario, is a longstanding clinical trial imaging core lab with cardiac and respiratory imaging experience. It directly competes with VIDA for respiratory and cardiac imaging endpoint work in biopharma-sponsored trials.

Broad incumbents

  • IQVIA: IQVIA is the world's largest CRO with embedded clinical trial imaging, real-world evidence, and data services. While broader and less specialized than VIDA, it competes for the same biopharma imaging endpoint budget and increasingly offers AI-driven imaging analytics as part of its portfolio.
  • ICON plc: ICON plc is a global CRO with significant imaging and biomarker capabilities following its PRA Health Sciences and other acquisitions. It competes with VIDA for biopharma clinical trial imaging contracts but at a much broader scale across all therapeutic areas.
  • Veeva Systems: Veeva provides cloud-based life sciences industry software, including Veeva Vault CTMS and eTMF for clinical trials. It is a broader incumbent in clinical trial technology that competes with VIDA's Intelligence Platform for sponsor platform budget.

Emerging players

  • Aidoc: Aidoc is a leading clinical AI imaging platform deployed across hospital systems, with FDA-cleared algorithms spanning multiple body parts. It is an emerging competitor in radiology AI infrastructure and could expand into respiratory imaging where VIDA is specialized.
  • Arterys (Tempus): Arterys, now part of Tempus, offers cloud-based AI medical imaging platforms with FDA-cleared algorithms for cardiac and lung MRI/CT. It is an emerging peer in clinical imaging AI infrastructure with comparable cloud-native architecture.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks6 records

Key highlights7 records

Customer concentration

VIDA social profiles

Digital presence

VIDA compliance and trust

Trust signal

Compliance9 records

VIDA financial estimates

Financial estimate

Revenue estimate

Valuation estimate

VIDA leadership team

Management profile

Number of profiles

Profiles8 records

VIDA funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

VIDA M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about VIDA

What does VIDA do?

VIDA Diagnostics provides AI-powered clinical trial imaging services and software to biopharma sponsors, enabling the collection, management, and analysis of quantitative imaging biomarkers throughout the drug development process. Its VIDA Intelligence Platform supports site management, trial orchestration, expert reading services, and AI-driven biomarker analysis across 1,500+ global sites, complemented by FDA-cleared clinical software (VIDA Insights/LungPrint) used by radiologists and pulmonologists at the point of care for early disease detection.

Is VIDA a public or private company?

VIDA is a private company. It is classified as venture growth investor backed and is currently operating.

When was VIDA founded?

VIDA was founded in 2009. It employs 51 to 100 people.

Where is VIDA based?

VIDA is headquartered in Coralville, United States, in the North America region.

How does VIDA make money?

Three revenue lines are on record. Clinical Trial Imaging Services are the primary driver. The others are software Licensing (VIDA Insights/LungPrint) and platform Access and Integration.

Who are VIDA's main competitors?

Direct peers on record are Median Technologies, Clario (formerly Bioclinica), Medidata (Dassault Systèmes), Riverain Technologies and Biomedical Systems (ERT/Clario). Broad incumbents are IQVIA, ICON plc and Veeva Systems. Emerging players are Aidoc and Arterys (Tempus).

Does VIDA have an API?

No public API is recorded for VIDA.

What industry is VIDA in?

VIDA's product category is Clinical Imaging Intelligence. Its primary akta.pro industry code is HLAGAJAM, Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF), with a secondary code of HLAGACAG, Clinical Trial Monitoring Support (On-site/Remote). Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Times of IndiaVIDA VX2 Plus KKR Edition unveiled: What's special about this e-scooterHero MotoCorp's electric mobility brand VIDA has unveiled a limited-edition VX2 Plus KKR Edition electric scooter featuring Kolkata Knight Riders branding, including the team's signature purple and gold colors with micro-dotted patterns and accent marks representing KKR's three IPL wins. The scooter comes with a matching limited-edition helmet and will be sold through select VIDA dealerships, though pricing has not yet been announced. Technically, the edition remains unchanged from the standard VX2 Plus, with a 3.4 kWh removable battery, 6 kW motor, 142 km IDC-certified range, and 4.3-inch TFT display with connected features.SecSEC FORM DVida Diagnostics Inc filed a Form D with the SEC to report an exempt securities offering under Rule 506(b), initiated on September 12, 2023. The company has sold approximately $10.8 million of its total $13.5 million offering to 21 investors, including the conversion of previously issued notes and accrued interest.Imaging Technology NewsPartnership with VIDA to streamline adoption of advanced MRI of the lungsPolarean Imaging partnered with VIDA Diagnostics to integrate xenon 129 MRI workflows into clinical care and create automated image processing. The collaboration aims to expand access to lung imaging and investigate new indications, with VIDA having empowered over 1,000 clinical and research sites.Sharecast.comPolarean Imaging enters strategic partnership with VIDA DiagnosticsPolarean Imaging announced a strategic partnership with VIDA Diagnostics to integrate VIDA's AI-enabled imaging platform into Polarean's xenon 129 MRI technology. The collaboration aims to standardize image acquisition and data-sharing methods, facilitating the use of these tools in clinical trials and routine care for chronic lung diseases. This initiative seeks to expand the applications of xenon 129 MRI in lung imaging services and develop new biomarkers.EIN PresswireVIDA Named One of the Fastest-Growing Private Companies in the USVIDA Diagnostics, a clinical imaging intelligence company based in Coralville, Iowa, announced on August 21, 2023 that it was named to the Inc. 5000 list of fastest-growing private U.S. companies. The ranking measures revenue growth from 2019 through 2022. VIDA's AI-powered cloud platform has empowered over 1,000 trial sites in less than two years.PR NewswireVIDA Launches VIDA Intelligence Portal 2.0 to Accelerate Onboarding of Clinical Trial SitesVIDA Diagnostics announced the launch of VIDA Intelligence Portal 2.0, a major upgrade to its AI-enabled platform designed to streamline clinical trial imaging operations and simplify site onboarding. The company reported that its global network of sites has expanded to over 1,000 in less than a year, with new agreements from RAYUS Radiology and several imaging groups in the US and Europe.PR NewswireStrong Demand for Lung Intelligence Accelerates VIDA's GrowthVIDA Diagnostics announced it secured financing to scale operations as demand for its AI-powered VIDA Intelligence Portal drives rapid growth, with the network expanding to over 1,000 sites globally within five months of launch. The funding round included Listwin Ventures, UW Health, Mathers Associates, University of Iowa Research Foundation, and Live Oak Bank, with proceeds supporting strategic senior hires and accelerated innovation. The company also received market authorization in Japan in April 2022 for its VIDA Insights software, complementing its existing regulatory clearances across the US, EU, Canada, and Australia.PR NewswireVIDA receives 510(k) clearance for deep learning-based enhancements to its LungPrint® solutionVIDA Diagnostics received 510(k) clearance from the FDA for deep learning-based enhancements to its LungPrint solution, including automated lung and lobe segmentation algorithms. This regulatory approval validates the quality and clinical efficacy of the company's AI-powered precision imaging technology for lung disease assessment. The enhanced solution improves diagnostic precision and enables physicians to develop personalized treatment plans for chronic respiratory conditions.PR NewswireVIDA appoints digital health technology leader Karen Drexler to board of directors, underscoring focus on market expansion of AI solutionsVIDA Diagnostics, Inc. appointed Karen Drexler to its board of directors to strengthen its leadership in digital health technology and support market expansion of AI solutions. The appointment aims to leverage Drexler's extensive entrepreneurial background and experience on other boards, such as ResMed, to modernize lung and respiratory care during the ongoing pandemic.PR NewswireVIDA Completes Second Close Of Round C FinancingVIDA Diagnostics, Inc. secured $2 million from OSF Ventures as part of a second close in its C round funding, following an $11 million investment last month. This funding will support the development of VIDA's AI-powered imaging solutions, particularly relevant during the COVID-19 pandemic and for chronic respiratory diseases. The investment underscores a strategic partnership aimed at enhancing patient care through advanced imaging technology.